Study on the Effect of Famotidine on Pharmacokinetics of Taletrectinib
← catalyst calendarNCT07742384 · readout in 167 d
Sponsored by Nuvation Bio Inc. (industry) · NUVB — their whole pipeline →.
Phase
Phase 1
Status
Not yet recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
56estimated
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-08-01 | estimated | When the study began enrolling |
| Primary completion | 2027-02-02 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-02-02 | estimated | The whole study's end, after follow-up |
| First posted | 2026-08-03 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-03 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Healthy Adult Participants
Interventions
- Drug: Taletrectinib
- Drug: Taletrectinib, Famotidine
- Drug: Taletrectinib, Famotidine
- Drug: Taletrectinib
- Drug: Taletrectinib, Famotidine
- Drug: Taletrectinib,Famotidine
Primary outcomes
what the primary-completion date above is the date OFCmax of Taletrectinib
measured Pre-dose to 264 hours post dose on Day 1, Day 15 and Day 30
AUClast of Taletrectinib
measured Pre-dose to 264 hours post dose on Day 1, Day 15 and Day 30
AUCinf of Taletrectinib
measured Pre-dose to 264 hours post dose on Day 1, Day 15 and Day 30
Permalink · NUVB's whole pipeline · Catalyst calendar · Every registered study · What changed